Dr. Braestrup is a member of the Board of Directors of Bavarian Nordic A/S, Chairman of the Board of Probiodrug AG and a member of the Boards of Santaris Pharma A/S and Evolva Holding SA. He is also a Member of the Advisory Board of Nordic Biotech and BankInvest BioMedical Venture.
Dr. Braestrup is a Member of The Royal Danish Scientific Society and The Academy of Technical Sciences. He holds M.Sc. degrees in Chemical Engineering and Biochemistry, and a Doctorate in Medical Science from the University of Copenhagen.
Dr. Braestrup was previously President and Chief Executive Officer at H. Lundbeck A/S. He also formerly held the positions of Vice President of Pharmaceutical Research, President of the CNS Division, and President of the Diabetes Care Division at Novo Nordisk A/S, and Head of Preclinical Drug Research with Schering AG.
Erik Walldén, CEO at Gyros, commented: "We welcome Claus to the Board of Directors. His excellent scientific background and many years’ experience within the biotech and pharmaceutical industry will be a great asset to Gyros."